Intellipharmaceutics International Inc. (IPCIF)
USD 0.15
(N/A%)
USD 0.15
(N/A%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 12 Million USD | 0.0% |
| 2022 | 12 Million USD | 17.14% |
| 2021 | 10.25 Million USD | 5.68% |
| 2020 | 9.7 Million USD | 31.59% |
| 2019 | 7.37 Million USD | 5.16% |
| 2018 | 7.01 Million USD | 2.22% |
| 2017 | 6.85 Million USD | 27.91% |
| 2016 | 5.36 Million USD | 80.8% |
| 2015 | 2.96 Million USD | -71.3% |
| 2014 | 10.33 Million USD | 143.58% |
| 2013 | 4.24 Million USD | -54.58% |
| 2012 | 9.34 Million USD | 194.2% |
| 2011 | 3.17 Million USD | -50.77% |
| 2010 | 6.44 Million USD | 544.88% |
| 2009 | 1 Million USD | -78.68% |
| 2008 | 4.69 Million USD | -68.84% |
| 2007 | 15.05 Million USD | -71.86% |
| 2006 | 53.51 Million USD | 209.84% |
| 2005 | 17.27 Million USD | 254.86% |
| 2004 | 4.86 Million USD | 128.76% |
| 2003 | 2.12 Million USD | 7.51% |
| 2002 | 1.97 Million USD | 129.09% |
| 2001 | 863.93 Thousand USD | 43.9% |
| 2000 | 600.35 Thousand USD | 20.27% |
| 1999 | 499.18 Thousand USD | 77.59% |
| 1998 | 281.09 Thousand USD | 89.39% |
| 1997 | 148.42 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 12.72 Million USD | 1.55% |
| 2024 Q3 | 14.44 Million USD | 13.52% |
| 2024 Q1 | 12.52 Million USD | 4.32% |
| 2023 Q3 | 11.58 Million USD | -1.27% |
| 2023 FY | 12 Million USD | 0.0% |
| 2023 Q2 | 11.73 Million USD | 7.64% |
| 2023 Q4 | 12 Million USD | 3.62% |
| 2023 Q1 | 10.9 Million USD | 6.37% |
| 2022 FY | 12 Million USD | 17.14% |
| 2022 Q1 | 9.86 Million USD | 1.74% |
| 2022 Q2 | 10 Million USD | 1.4% |
| 2022 Q3 | 9.62 Million USD | -3.82% |
| 2022 Q4 | 10.25 Million USD | 6.51% |
| 2021 Q1 | 8.43 Million USD | 12.66% |
| 2021 Q4 | 9.7 Million USD | 8.98% |
| 2021 Q2 | 9.37 Million USD | 11.06% |
| 2021 Q3 | 8.9 Million USD | -5.01% |
| 2021 FY | 10.25 Million USD | 5.68% |
| 2020 Q1 | 6.64 Million USD | -9.85% |
| 2020 FY | 9.7 Million USD | 31.59% |
| 2020 Q2 | 6.57 Million USD | -1.11% |
| 2020 Q3 | 6.57 Million USD | -0.03% |
| 2020 Q4 | 7.48 Million USD | 13.98% |
| 2019 FY | 7.37 Million USD | 5.16% |
| 2019 Q4 | 7.37 Million USD | -30.41% |
| 2019 Q2 | 7.69 Million USD | -5.14% |
| 2019 Q3 | 10.59 Million USD | 37.59% |
| 2019 Q1 | 8.11 Million USD | 15.77% |
| 2018 Q1 | 7.08 Million USD | 3.35% |
| 2018 FY | 7.01 Million USD | 2.22% |
| 2018 Q4 | 7.01 Million USD | -5.92% |
| 2018 Q3 | 7.45 Million USD | 6.85% |
| 2018 Q2 | 6.97 Million USD | -1.62% |
| 2017 Q3 | 3.61 Million USD | -37.56% |
| 2017 FY | 6.85 Million USD | 27.91% |
| 2017 Q1 | 4.86 Million USD | -9.21% |
| 2017 Q2 | 5.78 Million USD | 18.9% |
| 2017 Q4 | 6.85 Million USD | 89.76% |
| 2016 FY | 5.36 Million USD | 80.8% |
| 2016 Q2 | 3.69 Million USD | 18.05% |
| 2016 Q1 | 3.13 Million USD | 5.61% |
| 2016 Q3 | 3.87 Million USD | 4.88% |
| 2016 Q4 | 5.36 Million USD | 38.27% |
| 2015 Q4 | 2.96 Million USD | -13.53% |
| 2015 Q1 | 3.55 Million USD | -65.56% |
| 2015 Q2 | 3.82 Million USD | 7.48% |
| 2015 Q3 | 3.42 Million USD | -10.33% |
| 2015 FY | 2.96 Million USD | -71.3% |
| 2014 Q2 | 5.38 Million USD | 3.46% |
| 2014 Q1 | 5.2 Million USD | 22.65% |
| 2014 Q3 | 5.49 Million USD | 2.01% |
| 2014 FY | 10.33 Million USD | 143.58% |
| 2014 Q4 | 10.33 Million USD | 88.18% |
| 2013 Q1 | 7.93 Million USD | -15.03% |
| 2013 Q2 | 7.25 Million USD | -8.53% |
| 2013 FY | 4.24 Million USD | -54.58% |
| 2013 Q3 | 6.52 Million USD | -10.1% |
| 2013 Q4 | 4.24 Million USD | -34.98% |
| 2012 Q2 | 14.49 Million USD | -0.96% |
| 2012 Q3 | 11.43 Million USD | -21.08% |
| 2012 Q4 | 9.34 Million USD | -18.34% |
| 2012 FY | 9.34 Million USD | 194.2% |
| 2012 Q1 | 14.63 Million USD | 360.95% |
| 2011 FY | 3.17 Million USD | -50.77% |
| 2011 Q2 | 2.91 Million USD | -39.4% |
| 2011 Q4 | 3.17 Million USD | 14.65% |
| 2011 Q3 | 2.76 Million USD | -5.1% |
| 2011 Q1 | 4.81 Million USD | -25.34% |
| 2010 Q1 | 941.27 Thousand USD | -5.88% |
| 2010 Q2 | 1.18 Million USD | 25.54% |
| 2010 Q3 | 1.21 Million USD | 3.0% |
| 2010 Q4 | 6.44 Million USD | 429.9% |
| 2010 FY | 6.44 Million USD | 544.88% |
| 2009 Q4 | 1 Million USD | -45.33% |
| 2009 Q1 | 4.71 Million USD | 0.45% |
| 2009 Q2 | 2.54 Million USD | -45.93% |
| 2009 Q3 | 1.82 Million USD | -28.22% |
| 2009 FY | 1 Million USD | -78.68% |
| 2008 Q4 | 4.69 Million USD | 30.27% |
| 2008 FY | 4.69 Million USD | -68.84% |
| 2008 Q3 | 3.6 Million USD | 7.96% |
| 2008 Q2 | 3.33 Million USD | -49.89% |
| 2008 Q1 | 6.65 Million USD | -55.79% |
| 2007 Q1 | 44.06 Million USD | -17.66% |
| 2007 Q2 | 34.44 Million USD | -21.82% |
| 2007 Q3 | 23.17 Million USD | -32.74% |
| 2007 Q4 | 15.05 Million USD | -35.01% |
| 2007 FY | 15.05 Million USD | -71.86% |
| 2006 Q3 | 23.42 Million USD | 13.04% |
| 2006 FY | 53.51 Million USD | 209.84% |
| 2006 Q2 | 20.72 Million USD | 20.94% |
| 2006 Q1 | 17.13 Million USD | -0.81% |
| 2006 Q4 | 53.51 Million USD | 128.47% |
| 2005 FY | 17.27 Million USD | 254.86% |
| 2005 Q4 | 17.27 Million USD | 145.78% |
| 2005 Q3 | 7.02 Million USD | 46.29% |
| 2005 Q2 | 4.8 Million USD | -5.82% |
| 2005 Q1 | 5.1 Million USD | 4.79% |
| 2004 Q3 | 2.72 Million USD | 11.18% |
| 2004 Q2 | 2.45 Million USD | 59.86% |
| 2004 Q1 | 1.53 Million USD | -27.89% |
| 2004 FY | 4.86 Million USD | 128.76% |
| 2004 Q4 | 4.86 Million USD | 78.48% |
| 2003 Q4 | 2.12 Million USD | 106.92% |
| 2003 Q3 | 1.02 Million USD | -20.64% |
| 2003 Q2 | 1.29 Million USD | -43.4% |
| 2003 Q1 | 2.28 Million USD | 15.68% |
| 2003 FY | 2.12 Million USD | 7.51% |
| 2002 Q1 | 845 Thousand USD | -2.19% |
| 2002 Q2 | 1.02 Million USD | 21.89% |
| 2002 Q3 | 1.07 Million USD | 4.66% |
| 2002 Q4 | 1.97 Million USD | 83.6% |
| 2002 FY | 1.97 Million USD | 129.09% |
| 2001 Q3 | 434.64 Thousand USD | 55.44% |
| 2001 FY | 863.93 Thousand USD | 43.9% |
| 2001 Q1 | 646.48 Thousand USD | 7.68% |
| 2001 Q2 | 279.62 Thousand USD | -56.75% |
| 2001 Q4 | 863.93 Thousand USD | 98.77% |
| 2000 Q4 | 600.35 Thousand USD | 100.39% |
| 2000 FY | 600.35 Thousand USD | 20.27% |
| 2000 Q1 | 500.53 Thousand USD | 0.27% |
| 2000 Q3 | 299.59 Thousand USD | 0.14% |
| 2000 Q2 | 299.16 Thousand USD | -40.23% |
| 1999 Q3 | 63.27 Thousand USD | -53.92% |
| 1999 Q2 | 137.3 Thousand USD | -2.29% |
| 1999 Q1 | 140.52 Thousand USD | -50.01% |
| 1999 Q4 | 499.18 Thousand USD | 688.92% |
| 1999 FY | 499.18 Thousand USD | 77.59% |
| 1998 FY | 281.09 Thousand USD | 89.39% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | 145.11 Thousand USD | 0.0% |
| 1998 Q3 | 71.99 Thousand USD | -50.39% |
| 1998 Q4 | 281.09 Thousand USD | 290.44% |
| 1997 FY | 148.42 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -43674.895% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -26.863% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 83.43% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1384.774% |
| Rebus Holdings, Inc. | 5.24 Million USD | -129.088% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 79.651% |
| Qrons Inc. | 1.48 Million USD | -706.654% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -879.338% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 83.971% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -26767.655% |
| Skye Bioscience, Inc. | 14.07 Million USD | 14.663% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 77.472% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -25.326% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -2748.595% |
| SQZ Biotechnologies Company | 50.03 Million USD | 76.001% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -211.801% |
| Mesoblast Limited | 188.44 Million USD | 93.627% |
| Marizyme, Inc. | 26.67 Million USD | 54.982% |
| Genus plc | 485 Million USD | 97.524% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -105.537% |
| Pharming Group N.V. | 244.07 Million USD | 95.08% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -497.412% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -377.234% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -216.02% |
| ContraFect Corporation | 32.53 Million USD | 63.085% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -506.103% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -213.737% |
| IMV Inc. | 37.93 Million USD | 68.342% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -1.958% |
| MultiCell Technologies, Inc. | 1617.67 USD | -742249.614% |
| ONE Bio Corp. | 27.49 Million USD | 56.325% |
| Accustem Sciences Inc. | 1.07 Million USD | -1012.707% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 84.488% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -467.772% |
| Q BioMed Inc. | 8.13 Million USD | -47.656% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 85.52% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -133.36% |
| Biomind Labs Inc. | 1.49 Million USD | -701.326% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 89.885% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -32.808% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 34.747% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -737.513% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -8351.224% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -5871.065% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -109.0% |
| GB Sciences, Inc. | 5.41 Million USD | -121.664% |
| Alpha Cognition Inc. | 7.16 Million USD | -67.608% |
| HST Global, Inc. | 593.59 Thousand USD | -1923.064% |
| CSL Limited | 18.62 Billion USD | 99.936% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -853.688% |
| Halberd Corporation | 728.71 Thousand USD | -1547.928% |
| Enzolytics Inc. | 365.26 Million USD | 96.712% |
| Agentix Corp. | 2.51 Million USD | -378.331% |
| Resverlogix Corp. | 67.39 Million USD | 82.182% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1331.776% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 97.301% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -600.628% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 51.472% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -0.888% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -227.646% |
| AVAX Technologies, Inc. | 3.99 Million USD | -200.689% |
| Zenith Capital Corp. | 27.56 Thousand USD | -43458.95% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.094% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -4931.873% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -221.58% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1663.832% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -342.86% |
| Kadimastem Ltd | 3.5 Million USD | -242.631% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -17842.547% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 76.109% |
| BioStem Technologies, Inc. | 15.9 Million USD | 24.495% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -2484.203% |
| LadRx Corporation | 2.2 Million USD | -445.722% |
| Cell Source, Inc. | 15.8 Million USD | 24.027% |
| Regen BioPharma, Inc. | 5.45 Million USD | -120.037% |
| Regen BioPharma, Inc. | 5.45 Million USD | -120.037% |
| NovAccess Global Inc. | 7.86 Million USD | -52.769% |
| Affymax, Inc. | 8.87 Million USD | -35.371% |
| Itoco Inc. | 1.65 Million USD | -626.417% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -485.347% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -98.525% |
| Mobile Lads Corp. | 1.31 Million USD | -814.259% |
| CytoDyn Inc. | 127.89 Million USD | 90.61% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -28629.795% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -666.659% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -8.723% |
| SYBLEU INC | 681.41 Thousand USD | -1662.333% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -96.804% |
| International Stem Cell Corporation | 5.27 Million USD | -127.568% |
| Bioxytran, Inc. | 3.24 Million USD | -269.557% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1818.919% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -160.092% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 70.707% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 46.064% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -492.912% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -119.218% |
| Neutra Corp. | 973.52 Thousand USD | -1133.529% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 58.612% |
| PureTech Health plc | 125.58 Million USD | 90.438% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -219.626% |
| IXICO plc | 1.9 Million USD | -531.943% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 41.503% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 88.378% |
| CSL Limited | 18.62 Billion USD | 99.936% |
| Cellectis S.A. | 249.36 Million USD | 95.184% |